Research Article

Hubungan antara platelet lymphocyte ratio (PLR) dengan subtipe kanker payudara pada pasien kanker payudara di Rumah Sakit Umum Pusat Sanglah, Denpasar

I Gusti Ngurah Ari Aditya Satriya Wibawa , Ida Bagus Suryawisesa, I Ketut Widiana, I Gede Budhi Setiawan

I Gusti Ngurah Ari Aditya Satriya Wibawa
Residen Bedah Umum, Departemen Ilmu Bedah, Fakultas Kedokteran Universitas Udayana, Rumah Sakit Umum Pusat Sanglah, Denpasar, Bali. Email: ariadityasatriawibawa@gmail.com

Ida Bagus Suryawisesa
Divisi Bedah Onkologi, Departemen Ilmu Bedah, Fakultas Kedokteran Universitas Udayana, Rumah Sakit Umum Pusat Sanglah, Denpasar, Bali

I Ketut Widiana
Divisi Bedah Onkologi, Departemen Ilmu Bedah, Fakultas Kedokteran Universitas Udayana, Rumah Sakit Umum Pusat Sanglah, Denpasar, Bali

I Gede Budhi Setiawan
Divisi Bedah Onkologi, Departemen Ilmu Bedah, Fakultas Kedokteran Universitas Udayana, Rumah Sakit Umum Pusat Sanglah, Denpasar, Bali
Online First: December 01, 2020 | Cite this Article
Wibawa, I., Suryawisesa, I., Widiana, I., Setiawan, I. 2020. Hubungan antara platelet lymphocyte ratio (PLR) dengan subtipe kanker payudara pada pasien kanker payudara di Rumah Sakit Umum Pusat Sanglah, Denpasar. Intisari Sains Medis 11(3): 763-769. DOI:10.15562/ism.v11i3.834


Background: Breast cancer is one of the most diagnosed malignancies, as well as the leading cause of cancer mortality in women worldwide. The research objective was to analyze the relationship between PLR and breast cancer subtypes in breast cancer patients in Bali.
Methods: This study used a cross sectional design to assess how PLR could predict cancer subtypes in breast cancer patients involving 52 respondents by consecutive sampling.
Result: age ? 51 years is the most respondents, 69.7% with p-value 0.218. The location of the left breast tumor was found to be more than 63.2% with a p-value of 0.416. The best cut-off point lies at 162.1. PLR ? 162.1 with the luminal subtype of breast cancer, there were 22 respondents 66.7% with an OR of 4.3 (CI: 1.29-14.50) and a p-value of 0.015. The results of logistic regression analysis showed that PLR is the dominant factor causing the luminal subtype of breast cancer.
Conclusion: Age and location of the tumor were not associated with breast cancer subtypes. PLR was significantly positive, and the strength of the association was moderate with the non-luminal subtype of breast cancer. PLR values tended to be higher in non-luminal cancer subtypes compared to luminal cancer subtypes. PLR has a dominant effect on the age and location of the tumor on the non-luminal subtype of breast cancer.

 

Latar Belakang: Kanker payudara adalah salah satu keganasan yang paling banyak didiagnosis, serta penyebab mortalitas akibat kanker terbanyak pada wanita di seluruh dunia. Tujuan penelitian untuk menganalisis hubungan PLR dengan subtipe kanker payudara pada penderita kanker payudara di bali.

Metode: Penelitian ini menggunakan rancangan cross sectional untuk menilai bagaimana PLR dapat memprediksi subtipe kanker pada pasien kanker payudara yang melibatkan 52 responden secara consecutive sampling.
Hasil: umur ? 51 tahun merupakan responden terbanyak (69,7%) dengan p-value 0,218. lokasi tumor mammae kiri didapatkan lebih banyak (63,2%) dengan p-value 0,416. Cutt off point terbaik terletak pada angka 162,1. PLR ? 162,1 dengan subtipe luminal kanker payudara didapatkan sebanyak 22 responden (66,7%) dengan OR 4,3 (IK: 1,29-14,50) dan p-value 0,015. Hasil analisis regresi logistik didapatkan PLR merupakan faktor dominan yang menyebabkan subtipe luminal kanker payudara.
Kesimpulan: Umur dan lokasi tumor tidak berhubungan dengan subtipe kanker payudara. PLR berhubungan positif secara signifikan dan kekuatan hubungan moderate dengan subtipe non luminal kanker payudara. Nilai PLR cenderung tinggi didapatkan pada subtipe kanker non luminal dibandingkan dengan subtipe kanker luminal. PLR mempunyai pengaruh dominan dibandingkan dengan umur dan lokasi tumor terhadap subtipe non luminal kanker payudara.

 

References

Antonio V, Marlene D, Jeanette B, Eduardo B, and Maria E. Survival Prediction in Terminal Cancer Patients: A Systematic Review of the Medical Literature. Palliative Medicine. 2000;14: 363-374.

Asano Y, Kashiwagi S, Onoda N, Noda S, Kawajiri H, Takashima T, et al. Platelet–Lymphocyte Ratio as a Useful Predictor of the Therapeutic Effect of Neoadjuvant Chemotherapy in Breast Cancer. PLoS ONE. 2016;11: e0153459.

Bahgat, T. Breast Cancer Prognostication with Neutrophil–Lymphocyte Ratio and Platelet–Lymphocyte Ratio. PLoS One. 2019;15: 179.

Blows FM, Driver KE, Schmidt MK, Broeks A, et al. Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies. PLOS Medicine. 2010;e1000279.

Cuello LJ, Fidalgo ZA, Lopez AL, and Vasquez, TE. Platelet-to-Lymphocyte Ratio as a Predictive Factor of Complete Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer. PLoS One. 2018;13: e0207224.

Eley JW, Hill HA, Chen VW, Austin DF, Wesley MN, Muss HB, et al. Racial Differences in Survival from Breast Cancer. Results of the National Cancer Institute Black/White Cancer Survival Study. Jama. 1994;272: 947-54.

Faria SS, Fernandes PC, Silva MJB, Lima VC, et al. The Neutrophil-to-Lymphocyte Ratio: A Narrative Review. ecancermedicalscience. 2016;10: 702.

Fidler IJ. The Pathogenesis of Cancer Metastasis: The 'Seed and Soil' Hypothesis Revisited. Nat Rev Cancer. 2003;3: 453-8.

Franco AT, Corken A, and Ware J. Platelets at the Interface of Thrombosis, Inflammation, and Cancer. Blood. 2015;126: 582-588.

Gasic GJ, Gasic TB, and Stewart CC. Antimetastatic Effects Associated with Platelet Reduction. Proceedings of the National Academy of Sciences of the United States of America. 1968;61: 46-52.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, et al. Strategies for Subtypes--Dealing with the Diversity of Breast Cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22: 1736-47.

Gündüz S, Göksu SS, Arslan D, Tatli AM, Uysal M, et al. Factors Affecting Disease-Free Survival in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Who Receive Adjuvant Trastuzumab. Molecular and Clinical Oncology. 2015;3:1109-1112.

Guo W, Lu X, Liu Q, Zhang T, Li P, Qiao W, and Deng M. Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio for Breast Cancer Patients: An Updated Meta-Analysis of 17079 Individuals. Cancer Med. 2019;8: 4135-4148.

Gy?rffy, B., Hatzis, C., Sanft, T., Hofstatter, E., Aktas, B. & Pusztai, L. Multigene Prognostic Tests in Breast Cancer: Past, Present, Future. Breast Cancer Research : BCR. 2015;17: 11.

Jenne CN and Kubes P. Platelets in Inflammation and Infection. Platelets. 2015;26: 286-92.

Johnson MC. (Eds) Management of Breast Diseases. Springer, Cham. Anatomy and Physiology of the Breast. Management of Breast Diseases. 2016. pp 1-39.

Koh CH, Bhoo PN, Ng KL, Jabir RS, Tan GH, See MH, Jamaris S, and Taib NA. Utility of Pre-Treatment Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio as Prognostic Factors in Breast Cancer. Br J Cancer. 2015;113: 150-8.

Pilko KS, Langsenlehner U, Thurner EM, Stojakovic T, Pichler M, Gerger A, et al. The Elevated Preoperative Platelet-to-Lymphocyte Ratio Predicts Poor Prognosis in Breast Cancer Patients. Br J Cancer. 2014;110: 2524-30.

Liu C, Huang Z, Wang Q, Sun B, Ding L, Meng X, and Wu S. Usefulness of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Hormone-Receptor-Negative Breast Cancer. Onco Targets Ther. 2016;9: 4653-60.

Maltoni M, Caraceni A, Brunelli C, Broeckaert B, et al. Prognostic Factors in Advanced Cancer Patients: Evidence-Based Clinical Recommendations--a Study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol. 2005;23: 6240-8.

Mao Y, Keller ET, Garfield DH, Shen K, and Wang, J. Stroma Cells in Tumor Microenvironment and Breast Cancer. Cancer metastasis reviews. 2013;32: 303-315.

Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, and Honn KV. Platelets and Cancer: A Casual or Causal Relationship: Revisited. Cancer metastasis reviews. 2014;33: 231-269.

Okada F. Inflammation-Related Carcinogenesis: Current Findings in Epidemiological Trends, Causes and Mechanisms. Yonago Acta Medica. 2014;57: 65-72.

Patzelt J and Langer HF. Platelets in Angiogenesis. Curr Vasc Pharmacol. 2012;10: 570-7.

Sobri SB, Azhar Y, Wibisana IG, Rachman A. Manajemen Terkini Kanker Payudara. 2017.

Sohn YM, Han K, and Seo M. Immunohistochemical Subtypes of Breast Cancer: Correlation with Clinicopathological and Radiological Factors. Iranian Journal of Radiology. 2016;13:e31386.

Templeton AJ, Ace O, Mcnamara MG, et al. Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. Cancer Epidemiol Biomarkers Prev, 2014;23:1204-12.

Weigelt B, Peterse JL, and Van TLJ. Breast Cancer Metastasis: Markers and Models. Nat Rev Cancer. 2005;5: 591-602.

Yan M and Jurasz P. The Role of Platelets in the Tumor Microenvironment: From Solid Tumors to Leukemia. Biochim Biophys Acta. 2016;p392-400.

Yersal Ö, Çetinkünar S, Aktimur R, Aziret M, Özda? S, et al. Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratios Are Not Different among Breast Cancer Subtypes. Asian Pacific Journal of Cancer Prevention:APJCP. 2017;18: 2227-2231.

Zenan H, Zixiong L, Zhicheng, Y, Mei H, Xiongbin Y, et al. Clinical Prognostic Evaluation of Immunocytes in Different Molecular Subtypes of Breast Cancer. J Cell Physiol. 2019;234: 20584-20602.

Zhang M, Huang XZ, Song YX, et al. High Platelet-to-Lymphocyte Ratio Predicts Poor Prognosis and Clinicopathological Characteristics in Patients with Breast Cancer: A Meta-Analysis. BioMed Research International, 2017: 9503025.


No Supplementary Material available for this article.
Article Views      : 33
PDF Downloads : 18